Distinct clinical, laboratory, molecular, and pathologic features of systemic mastocytosis involving the gastrointestinal tract
Am J Clin Pathol · 2025
DOI: 10.1093/ajcp/aqaf112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Am J Clin Pathol, 2025. Verfasst von April Chiu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematopathology, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Mastocytosis, Systemic, Gastrointestinal Tract. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, Department of Laboratory Medicine and Pathology.
Abstract (Originalsprache)
Objective
Gastrointestinal (GI) symptoms are common in systemic mastocytosis (SM). We hereby report the clinicopathologic and molecular features of GI mastocytosis.
Methods
The study includes 104 patients with suspected SM. Of 258 GI biopsy specimens, 33 (20 patients, 19%) were mastocytosis-positive, with 19 (16 patients) initially missed.
Results
Tryptase (n = 29) was weakly positive/negative in two-thirds of the mastocytosis-positive GI biopsy specimens. Additional immunohistochemistry (n = 23) showed positive mast cell expression for CD30 (n = 2), CD123 (n = 7), and PD-L1 (n = 12), as well as increased PD-1–positive cells (n = 4). Sixty patients had positive bone marrow (BM) for SM (SM-BM+), including 19 with positive GI biopsy specimens (SM-GI+). Almost all (43/44) SM-BM– patients were SM-GI–. The SM-GI vs SM-BM status showed high positive predictive value (95%) and specificity (98%). Patients with SM with mastocytosis-positive vs mastocytosis-negative GI biopsy specimens had higher serum tryptase levels (P = .04). KIT D816V mutation was detected in 7 of 13 and 12 of 13 mastocytosis-positive GI biopsy specimens using allele-specific polymerase chain reaction and droplet digital polymerase chain reaction (ddPCR), respectively.
Conclusions
GI mastocytosis is highly predictive of SM in BM; however, most SM-BM+ patients are SM-GI–. The SM-BM– patients are very unlikely to be SM-GI+. Because GI neoplastic mast cells are often tryptase negative, diagnostic evaluation should include CD117 and CD25 immunohistochemistry, as well as KIT D816V mutation analysis by ddPCR as needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematopathology, Mayo Clinic, Rochester, MN, United States.
- Division of Hematology, Mayo Clinic, Rochester, MN, United States.
Förderung
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
- Department of Laboratory Medicine and Pathology
Zitieren
APA
Chiu, A., Viswanatha, D. S., He, R., Majerus, J. A., Reichard, K. K., Tefferi, A., Pardanani, A., & Chen, D. (2025). Distinct clinical, laboratory, molecular, and pathologic features of systemic mastocytosis involving the gastrointestinal tract. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqaf112
Vancouver
Chiu A, Viswanatha DS, He R, Majerus JA, Reichard KK, Tefferi A, et al. Distinct clinical, laboratory, molecular, and pathologic features of systemic mastocytosis involving the gastrointestinal tract. Am J Clin Pathol. 2025. doi:10.1093/ajcp/aqaf112
BibTeX
@article{Chiu2025,
author = {Chiu, April and Viswanatha, David S and He, Rong and Majerus, Julie A and Reichard, Kaaren K and Tefferi, Ayalew and Pardanani, Animesh and Chen, Dong},
title = {Distinct clinical, laboratory, molecular, and pathologic features of systemic mastocytosis involving the gastrointestinal tract},
journal = {Am J Clin Pathol},
year = {2025},
doi = {10.1093/ajcp/aqaf112}
}
EUVIMED